Investor Relations :: Immunovant, Inc. (IMVT)

Company Overview

As a leader in the FcRn inhibitor technology, Immunovant, Inc is focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing batoclimab (“IMVT-1401”) and IMVT-1402. Each of these assets is a novel, fully human anti-FcRn monoclonal antibody in development as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Download Corporate Presentation

Stock Quote

Roivant Investor Day

Sep 28, 2022 11:00 am EDT

View Event

View all news

Latest News

Feb 3, 2023

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

Nov 7, 2022

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

Nov 4, 2022

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

View all news

Corporate Presentation

View Presentation

IR Contacts

Company

Immunovant, Inc.
320 W 37th Street
6th Floor
New York, NY 10018

Investor Relations

Immunovant, Inc.
Chau Cheng, PhD, MBA
Investor Relations
info@immunovant.com

Transfer Agent

Continental Stock Transfer & Trust Company, LLC
1 State Street
30th Floor
New York, NY 10004
T: 212-509-4000
cstmail@continentalstock.com